XML 42 R30.htm IDEA: XBRL DOCUMENT v3.8.0.1
1. ORGANIZATION, LIQUIDITY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
12 Months Ended
Mar. 31, 2018
Mar. 31, 2017
Noncontrolling interests $ (101,246) $ (80,967)
Cash equivalents 0 0
Asset impairment charges $ 0 $ 0
Shares considered antidilutive 7,160,004 3,908,292
Amortization of deferred financing costs $ 0 $ 27,641
Contract revenue 149,625 392,073
Research and development expenses 586,000 673,000
NIH Milestone [Member]    
Contract revenue $ 149,625  
DARPA [Member]    
Contract revenue   387,438
Battelle    
Contract revenue   4,635
ESI [Member]    
Equity ownership percentage 80.00%  
Noncontrolling interest percentage 20.00%  
Noncontrolling interests $ (101,246) $ (80,967)